UniCredit Bank AG (UB2Y5K) News

Form 424B5 - Prospectus [Rule 424(b)(5)]

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a...

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC...

Form S-1 - General form for registration of securities under the Securities Act of 1933

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Agreement enhances Company’s intellectual property portfolio SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE...

Form 8-K - Current report

Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders

Extensive Issued and Pending IP Patent Applications Acquired with License Agreement SARASOTA, FL, July 08...

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Amplify Bio to complete GLP study of SPC-15 Novel Intranasal Therapeutic Silo study advances SPC-15 towards...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form 4 - Statement of changes in beneficial ownership of securities

Form D - Notice of Exempt Offering of Securities

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Analytical testing has confirmed optimal formulation for upcoming studies SARASOTA, FL, June 07, 2024 (GLOBE...

Form 8-K - Current report

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SARASOTA, FL, June 06, 2024 (GLOBE NEWSWIRE) -- SARASOTA, FL, June 6, 2024 (GLOBE NEWSWIRE) -- Silo Pharma...

Form 424B5 - Prospectus [Rule 424(b)(5)]